Mesh.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « Mesh.i » - entrée « Enzyme Inhibitors »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Enzyme Induction < Enzyme Inhibitors < Enzyme Stability  Facettes :

List of bibliographic references indexed by Enzyme Inhibitors

Number of relevant bibliographic references: 17.
Ident.Authors (with country if any)Title
000678 (2015) Ross B. Mounsey [Royaume-Uni] ; Sarah Mustafa [Royaume-Uni] ; Lianne Robinson [Royaume-Uni] ; Ruth A. Ross [Canada] ; Gernot Riedel [Royaume-Uni] ; Roger G. Pertwee [Royaume-Uni] ; Peter Teismann [Royaume-Uni]Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
001612 (2011) C. Gibrat ; F. CicchettiPotential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
001C52 (2010) A. Jon Stoessl [Canada]Continuous dopaminergic therapy in Parkinson disease: Time to stride back?
001E78 (2009) Moonhee Lee [Canada] ; Claudia Schwab ; Sheng Yu ; Edith Mcgeer ; Patrick L. McgeerAstrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide.
002285 (2008) Andis Klegeris [Canada] ; Jane Li [États-Unis] ; Theo K. Bammler [États-Unis] ; Jinghua Jin [États-Unis] ; David Zhu [États-Unis] ; Daniel T. Kashima [États-Unis] ; Sheng Pan [États-Unis] ; Sadayuki Hashioka [Canada] ; John Maguire [Canada] ; Patrick L. Mcgeer [Canada] ; Jing Zhang [États-Unis]Prolyl endopeptidase is revealed following SILAC analysis to be a novel mediator of human microglial and THP‐1 cell neurotoxicity
002A01 (2005) Tom H. Johnston [Canada] ; Susan H. Fox ; Jonathan M. BrotchieAdvances in the delivery of treatments for Parkinson's disease.
002F79 (2002) F E Parkinson [Canada] ; C J D. Sinclair ; T. Othman ; N J Haughey ; J D GeigerDifferences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions.
002F83 (2002) Byron M. Garnham [Canada] ; Shirley Fitzpatrick-Wong ; Walter Schunack ; Bernd Nürnberg ; Giuseppe Sorrentino ; Fiona E. Parkinson ; Julian N. Kanfer ; Daniel S. SitarActivation of phospholipases A2 and D of a human neuroblastoma cell line (LA-N-2) by N-dodecyl-L-lysine amide (compound 24), a putative G protein activator: characteristics of inhibition by (-)-nicotine.
003112 (2001) C J Sinclair [Canada] ; A E Powell ; W. Xiong ; C G Larivière ; S A Baldwin ; C E Cass ; J D Young ; F E ParkinsonNucleoside transporter subtype expression: effects on potency of adenosine kinase inhibitors.
003362 (2000) C J Sinclair [Canada] ; C G Larivière ; J D Young ; C E Cass ; S A Baldwin ; F E ParkinsonPurine uptake and release in rat C6 glioma cells: nucleoside transport and purine metabolism under ATP-depleting conditions.
003372 (2000) L. McauleyEntacapone: adjunctive use in patients with advanced Parkinson's disease.
003808 (1999) M. Guttman [Canada] ; O. Suchowersky [Canada]Parkinson's disease management : Towards a new paradigm
003836 (1999) J. Rivest [Canada] ; C. L. Barclay [Canada] ; O. Suchowersky [Canada]COMT inhibitors in Parkinson's disease
003858 (1998) R P Lee ; A. Parkinson ; P G ForkertIsozyme-selective metabolism of ethyl carbamate by cytochrome P450 (CYP2E1) and carboxylesterase (hydrolase A) enzymes in murine liver microsomes.
003A14 (1998) A. H. Rajput [Canada] ; W. Martin [Canada] ; M.-H. Saint-Hilaire [États-Unis] ; E. Dorflinger [États-Unis] ; S. Pedder [États-Unis]Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon : A double-blind, placebo-controlled, multicenter trial
003C61 (1997) D. J. Doudet [Canada] ; G. L. Y. Chan [Canada] ; J. E. Holden [États-Unis] ; K. S. Morrison [Canada] ; R. J. Wyatt [États-Unis] ; T. J. Ruth [Canada]Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced Parkinsonism in monkeys
005588 (????) D J Chong [Canada] ; O. Suchowersky ; C. Szumlanski ; R M Weinshilboum ; R. Brant ; N R CampbellThe relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Enzyme Inhibitors" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Enzyme Inhibitors" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Enzyme Inhibitors
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022